Clinical Trial Update: Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating canakinumab to prevent progression to cancer in patients with clonal cytopenias of undetermined significance; the study is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clonal Cytopenia of Undetermined Significance

Drugs mentioned

• ILARIS (canakinumab)

Snippet

Sponsor: Uma Borate | Conditions: Clonal Cytopenia of Undetermined Significance | Phase 2 | Status: RECRUITING